Skye Bioscience’s Q3 2025: Strong clinical upside offsets widening losses

In the third quarter of 2025, Skye Bioscience, Inc. (Nasdaq: SKYE) reported a net loss of $12.8 million, with research‑and‑development expenses rising to $9.4 million from $4.9 million a year earlier. On the upside, the company revealed promising results from its Phase 2a trial of nimacimab in obesity: when combined with semaglutide, weight‑loss outcomes improved by about 29 % relative to semaglutide alone, and rebound weight gain after treatment was significantly reduced (18.1 % vs 49.8 %). The company ended the quarter with $35.3 million in cash and equivalents, a runway the firm says supports operations into 2027 as it advances next‑stage trials and manufacturing efforts. While the clinical data suggest a differentiated mechanism and clean safety profile for nimacimab (no neuropsychiatric adverse events reported) — a positive signal in a crowded obesity‑treatment space — investors will be watching closely for the upcoming 26‑week extension read‑out (43 patients enrolled) expected in Q1 2026, and how dosing strategy evolves. #SkyeBioscience #Nimacimab #ObesityTreatment #BiotechNews #SlimScan #GrowthStocks #CANSLIM